Cure8 research brief
Methotrexate is commonly used in IBD, often with biologics, but real‑world data on how long patients stay on it, typical dosing, and safety in large contemporary cohorts are limited.
This study provides practical, large‑scale information that could inform patients and clinicians weighing methotrexate as a treatment option.
Adult IBD patients (particularly Crohn’s disease), clinicians prescribing methotrexate or biologics, and researchers interested in real‑world medication persistence and safety.
The MICI‑METHO study included 1,115 adult IBD patients treated with methotrexate between 2015–2022 across 15 French centers. About three‑quarters had Crohn’s disease; most patients received methotrexate in combination with other therapies and a common dose was 15 mg/week for induction and maintenance.
Median persistence was reported as ~27.7 months for Crohn’s and ~22.4 months for ulcerative colitis. Roughly one‑third of patients experienced an adverse event attributed to methotrexate; nine had serious adverse events.
As a retrospective multicenter study, findings reflect real‑world practice across French centers from 2015–2022; the design cannot prove causation and local prescribing/monitoring patterns may differ elsewhere.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...
This gives adults with moderately to severely active Crohn’s disease another FDA‑approved biologic option, including for people who did not respond to or could not tolerate other therapies.
A new FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderate-to-severe Crohn disease another treatment option with one-year trial data showing improved clinical remission and endoscopic healing versus...
